Accepted Manuscript

Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study

NEUROLOGICAL SCIENCES

Vincent Planche, Xavier Moisset, Remy Morello, Emilie Dumont, Marion Gibelin, Julie Charré-Morin, Aurore Saubusse, Audrey Mondou, Françoise Reuter, Gilles Defer, Jean Pelletier, Bruno Brochet, Pierre Clavelou

PII: S0022-510X(17)34373-3 DOI: doi:10.1016/j.jns.2017.10.008

Reference: JNS 15603

To appear in: Journal of the Neurological Sciences

Received date: 31 July 2017

Revised date: 25 September 2017 Accepted date: 5 October 2017

Please cite this article as: Vincent Planche, Xavier Moisset, Remy Morello, Emilie Dumont, Marion Gibelin, Julie Charré-Morin, Aurore Saubusse, Audrey Mondou, Françoise Reuter, Gilles Defer, Jean Pelletier, Bruno Brochet, Pierre Clavelou, Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Jns(2017), doi:10.1016/j.jns.2017.10.008

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab:

A 3-year follow-up multicentric study

Vincent Planche¹, Xavier Moisset^{1,2}, Remy Morello³, Emilie Dumont¹, Marion Gibelin⁴, Julie Charré-Morin⁵, Aurore Saubusse⁵, Audrey Mondou⁶, Françoise Reuter⁷, Gilles Defer⁶, Jean Pelletier⁷, Bruno Brochet⁵ and Pierre Clavelou^{1,2}

¹ Service de Neurologie, CHU de Clermont-Ferrand, Université Clermont Auvergne, F-63000, Clermont-Ferrand, France

² Neuro-Dol, Inserm U1107, Université Clermont Auvergne, F-63000, Clermont-Ferrand, France

³ Unité de Biostatistique et Recherche Clinique, CHU de Caen, Université de Normandie, F-14033, Caen, France

⁴ Réseau NeuroSEP Auvergne, F-63110, Beaumont, France

⁵ Service de Neurologie, CHU de Bordeaux, Université de Bordeaux, F-33007, Bordeaux, France

⁶ Service de Neurologie, CHU de Caen, Université de Normandie, F-14033, Caen, France

⁷ APHM, Hôpital de la Timone, Pôle de Neurosciences Cliniques, Service de Neurologie, F-13000, Marseille, France

Corresponding author: Dr Vincent Planche, Service de Neurologie, CHU Clermont-Ferrand, 58 rue Montalembert, F-63000, Clermont-Ferrand, France; planche.vincent@gmail.com; tel.: 33 (0)4 73 75 22 05; fax: 33 (0)4 73 75 22 06

Word count: Abstract: 232, Article: 2535

Tables: 5. Figure: 1. References: 30

Keywords: health-related quality of life, multiple sclerosis, natalizumab, fatigue, depression, cognition

Download English Version:

https://daneshyari.com/en/article/5502480

Download Persian Version:

https://daneshyari.com/article/5502480

<u>Daneshyari.com</u>